Clinical trials: Renal Hemodynamics
CHF, Renal Disease
Validation of a Sensor for Non-Invasive Measurements
Subjects will be measured with both a sensor and a reference device
- Conditions
- CHF, Renal Disease, Hypertension
- Trial name
- NCT03463148
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Baxter Healthcare Corporation
Hemodynamic Monitoring
Starling/CRRT Observational Study
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes.
- Trial name
- NCT05729048
- Testing
- Starling
- Where
- United States
- Sponsor
- Baxter Healthcare Corporation
Systemic Inflammatory Response Syndrome, Kidney Failure, Acute
High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock
This study will assess the influence of the High Cut-Off (HCO) CVVHD treatment on the disease progression in septic patients. The primary aim of the study is to evaluate whether HCO CVVHD leads to a significant improvement of the…
- Trial name
- HICOSS (NCT00875888)
- Testing
- continuous venovenous hemodialysis
- Where
- 4 sites in Austria, Germany
- Volunteers
- 80 people
- Sponsor
- Vantive Health LLC
Healthy
Effect of Azimilide Dihydrochloride on Renal Function
This study will assess the effect of multiple dosing of 125 mg azimilide on glomerular filtration rate (GFR) and total creatinine clearance (GFR + active secretion) in healthy subjects.
- Trial name
- NCT00318838
- Testing
- Azimilide dihydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Chronic Kidney Disease
Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment
Primary Objective: To assess the tolerability and safety of repeated oral ascending doses of SAR407899A in patients with moderate chronic kidney disease (CKD) on stable angiotensin converting enzyme-inhibitor (ACE-I) Secondary…
- Trial name
- NCT01485900
- Testing
- SAR407899A
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 20 people
- Sponsor
- Sanofi
Hypertension
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
- Trial name
- NCT00518765
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Type 1
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
Protein kinase C (PKC), an enzyme in the body, has been implicated in the process of diabetic microvascular complications. The purpose of this study will be to evaluate the renal hemodynamic and peripheral vascular effects of PKC…
- Trial name
- NCT00297401
- Testing
- ruboxistaurin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Chromaderm, Inc.
AKI - Acute Kidney Injury, Cardiac Surgery
Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device.
- Conditions
- AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability
- Trial name
- NCT07022314
- Testing
- FIZE kUO®
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- FIZE Medical ltd
β-thalassemia, Transfusional Iron Overload
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).
- Trial name
- NCT00560820
- Testing
- Deferasirox
- Where
- 3 sites in Italy
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure (CHF)
Recombinant Human Relaxin for the Treatment of Decompensated CHF
Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF
- Trial name
- NCT00406575
- Testing
- Recombinant human relaxin (rhRlx)
- Where
- 2 sites in Russia
- Volunteers
- 11 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Chronic Heart Failure (CHF)
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
- Trial name
- NCT01546532
- Testing
- RLX030
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Autosomal Dominant Polycystic Kidney Disease
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.
- Trial name
- NCT01336972
- Testing
- Tolvaptan
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Moderate to High-risk Noncardiac Surgery
SMART TRENDS Study
A multicenter, interventional, feasibility comparison with historical controls
- Trial name
- NCT05957406
- Testing
- Acumen HPI Smart Alerts and Smart Trends Software, The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff
- Where
- 8 sites in United States
- Volunteers
- 296 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 2
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.
- Trial name
- NCT00238472
- Testing
- nateglinide
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Cirrhosis, Ascites
Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
Effects of long term albumin administration on the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.
- Trial name
- NCT00968695
- Testing
- Albumin
- Where
- 6 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Instituto Grifols, S.A.
Renal Hemodynamics
Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide
This phase 1 study is an 8-day treatment period, randomized, controlled, double-blind, 3 parallel-groups, monocentric study. The primary objective is to evaluate the effect of naproxcinod on the renal function when…
- Trial name
- NCT00909519
- Testing
- naproxcinod, Naproxen, furosemide
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- NicOx
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or…
- Trial name
- NCT00660309
- Testing
- Aliskiren, Irbesartan, Captopril
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Novartis